Literature DB >> 34699027

Implications of Phosphoinositide 3-Kinase-Akt (PI3K-Akt) Pathway in the Pathogenesis of Alzheimer's Disease.

Manish Kumar1, Nitin Bansal2.   

Abstract

Alzheimer's disease (AD) is the foremost type of dementia that afflicts considerable morbidity and mortality in aged population. Several transcription molecules, pathways, and molecular mechanisms such as oxidative stress, inflammation, autophagy, and immune system interact in a multifaceted way that disrupt physiological processes (cell growth, differentiation, survival, lipid and energy metabolism, endocytosis) leading to apoptosis, tauopathy, β-amyloidopathy, neuron, and synapse loss, which play an important role in AD pathophysiology. Despite of stupendous advancements in pathogenic mechanisms, treatment of AD is still a nightmare in the field of medicine. There is compelling urgency to find not only symptomatic but effective disease-modifying therapies. Recently, phosphoinositide 3-kinase (PI3K) and Akt are identified as a pathway triggered by diverse stimuli, including insulin, growth factors, cytokines, and cellular stress, that link amyloid-β, neurofibrillary tangles, and brain atrophy. The present review aims to explore and analyze the role of PI3K-Akt pathway in AD and agents which may modulate Akt and have therapeutic prospects in AD. The literature was researched using keywords "PI3K-Akt" and "Alzheimer's disease" from PubMed, Web of Science, Bentham, Science Direct, Springer Nature, Scopus, and Google Scholar databases including books. Articles published from 1992 to 2021 were prioritized and analyzed for their strengths and limitations, and most appropriate ones were selected for the purpose of review. PI3K-Akt pathway regulates various biological processes such as cell proliferation, motility, growth, survival, and metabolic functions, and inhibits many neurotoxic mechanisms. Furthermore, experimental data indicate that PI3K-Akt signaling might be an important therapeutic target in treatment of AD.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Acetylcholine; Amyloid; Inflammation; Neurofibrillary tangles; Neuroprotection; Oxidative stress

Mesh:

Substances:

Year:  2021        PMID: 34699027     DOI: 10.1007/s12035-021-02611-7

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  237 in total

Review 1.  Cholinergic system during the progression of Alzheimer's disease: therapeutic implications.

Authors:  Elliott J Mufson; Scott E Counts; Sylvia E Perez; Stephen D Ginsberg
Journal:  Expert Rev Neurother       Date:  2008-11       Impact factor: 4.618

2.  Signalling mechanisms mediated by the phosphoinositide 3-kinase/Akt cascade in synaptic plasticity and memory in the rat.

Authors:  Jennifer M Horwood; Franck Dufour; Serge Laroche; Sabrina Davis
Journal:  Eur J Neurosci       Date:  2006-06       Impact factor: 3.386

3.  Effects of nicorandil in neuroprotective activation of PI3K/AKT pathways in a cellular model of Alzheimer's disease.

Authors:  Jingjing Kong; Guiru Ren; Ning Jia; Yanfu Wang; Hua Zhang; Wei Zhang; Bingkun Chen; Yunpeng Cao
Journal:  Eur Neurol       Date:  2013-09-04       Impact factor: 1.710

Review 4.  Lipid signaling in neural plasticity, brain repair, and neuroprotection.

Authors:  Nicolas G Bazan
Journal:  Mol Neurobiol       Date:  2005-08       Impact factor: 5.590

5.  Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin.

Authors:  C G Jolivalt; C A Lee; K K Beiswenger; J L Smith; M Orlov; M A Torrance; E Masliah
Journal:  J Neurosci Res       Date:  2008-11-15       Impact factor: 4.164

Review 6.  Dementia syndromes: evaluation and treatment.

Authors:  Kevin R Scott; Anna M Barrett
Journal:  Expert Rev Neurother       Date:  2007-04       Impact factor: 4.618

Review 7.  Alzheimer's disease and vascular dementia in developing countries: prevalence, management, and risk factors.

Authors:  Raj N Kalaria; Gladys E Maestre; Raul Arizaga; Robert P Friedland; Doug Galasko; Kathleen Hall; José A Luchsinger; Adesola Ogunniyi; Elaine K Perry; Felix Potocnik; Martin Prince; Robert Stewart; Anders Wimo; Zhen-Xin Zhang; Piero Antuono
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

8.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

Review 9.  Tau and neuroinflammation: What impact for Alzheimer's Disease and Tauopathies?

Authors:  Cyril Laurent; Luc Buée; David Blum
Journal:  Biomed J       Date:  2018-03-20       Impact factor: 4.910

Review 10.  Current Research Therapeutic Strategies for Alzheimer's Disease Treatment.

Authors:  Jaume Folch; Dmitry Petrov; Miren Ettcheto; Sonia Abad; Elena Sánchez-López; M Luisa García; Jordi Olloquequi; Carlos Beas-Zarate; Carme Auladell; Antoni Camins
Journal:  Neural Plast       Date:  2016-01-03       Impact factor: 3.599

View more
  9 in total

Review 1.  Current Progress on Neuroprotection Induced by Artemisia, Ginseng, Astragalus, and Ginkgo Traditional Chinese Medicines for the Therapy of Alzheimer's Disease.

Authors:  Qin Li; Limor Rubin; Marta Silva; Shuai Li; Chao Yang; Philip Lazarovici; Wenhua Zheng
Journal:  Oxid Med Cell Longev       Date:  2022-06-14       Impact factor: 7.310

Review 2.  Primary cilia in the postnatal brain: Subcellular compartments for organizing neuromodulatory signaling.

Authors:  Lauren Tereshko; Gina G Turrigiano; Piali Sengupta
Journal:  Curr Opin Neurobiol       Date:  2022-04-08       Impact factor: 7.070

Review 3.  Neuroprotective Effects of Cholinesterase Inhibitors: Current Scenario in Therapies for Alzheimer's Disease and Future Perspectives.

Authors:  Natália Chermont Dos Santos Moreira; Jéssica Ellen Barbosa de Freitas Lima; Marcelo Fiori Marchiori; Ivone Carvalho; Elza Tiemi Sakamoto-Hojo
Journal:  J Alzheimers Dis Rep       Date:  2022-04-18

4.  Bezafibrate Exerts Neuroprotective Effects in a Rat Model of Sporadic Alzheimer's Disease.

Authors:  Li-Fan Lin; Yun-Ting Jhao; Chuang-Hsin Chiu; Lu-Han Sun; Ta-Kai Chou; Chyng-Yann Shiue; Cheng-Yi Cheng; Kuo-Hsing Ma
Journal:  Pharmaceuticals (Basel)       Date:  2022-01-18

Review 5.  Long Non-Coding RNA in Gastric Cancer: Mechanisms and Clinical Implications for Drug Resistance.

Authors:  Ying Liu; Xiang Ao; Yu Wang; Xiaoge Li; Jianxun Wang
Journal:  Front Oncol       Date:  2022-01-28       Impact factor: 6.244

Review 6.  miR-484: A Potential Biomarker in Health and Disease.

Authors:  Yin-Zhao Jia; Jing Liu; Geng-Qiao Wang; Zi-Fang Song
Journal:  Front Oncol       Date:  2022-03-09       Impact factor: 6.244

7.  Network Pharmacology-Based Strategy to Investigate the Pharmacologic Mechanisms of Coptidis Rhizoma for the Treatment of Alzheimer's Disease.

Authors:  Xian-Wen Ye; Hai-Li Wang; Shui-Qing Cheng; Liang-Jing Xia; Xin-Fang Xu; Xiang-Ri Li
Journal:  Front Aging Neurosci       Date:  2022-06-21       Impact factor: 5.702

8.  A circular RNA blood panel that differentiates Alzheimer's disease from other dementia types.

Authors:  Ziye Ren; Changbiao Chu; Yana Pang; Huimin Cai; Longfei Jia
Journal:  Biomark Res       Date:  2022-08-18

9.  Aerobic Exercise Regulates Apoptosis through the PI3K/Akt/GSK-3β Signaling Pathway to Improve Cognitive Impairment in Alzheimer's Disease Mice.

Authors:  Yan Peng; Rui Chi; Gang Liu; Weijie Tian; Jun Zhang; Rihui Zhang
Journal:  Neural Plast       Date:  2022-09-10       Impact factor: 3.144

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.